Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pozanicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 2/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 2/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.73 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.73 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pozanicline SCHEMBL1538473 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL29378392 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL7367252 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL29711154 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL7838537 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL5139644 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL7373407 | 0.89 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL905231 | 0.89 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Hydrochloric Acid SCHEMBL7450656 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Hydrochloric Acid SCHEMBL7415362 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-3713574-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | The Governors of the University of Alberta (CA) | 2020-09-30 | — | — | EP | claimed |
| CN-111629726-A | Method for combatting respiratory depression by activating neuronal heterotopic nicotinic acetylcholine receptors | 阿尔伯塔大学理事会 | 2020-09-04 | — | — | CN | claimed |
| WO-2019100155-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-05-31 | — | — | WO | claimed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | claimed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | claimed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | claimed |
| WO-2010138600-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-20020028798-A1 | Irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS | 2002-03-07 | — | — | US | claimed |
| EP-0663912-B1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LAB (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000023062-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | OMEROS MEDICAL SYSTEMS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-6033685-A | Tablet for the controlled release of active agents | ABBOTT LABORATORIES (US) | 2000-03-07 | — | — | US | claimed |
| EP-0951279-A1 | TABLET FOR THE CONTROLLED RELEASE OF ACTIVE AGENTS | Abbott Laboratories (US) | 1999-10-27 | — | — | EP | claimed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | claimed |
| WO-1998030208-A1 | TABLET FOR THE CONTROLLED RELEASE OF ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0663912-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0663912-A4 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. | ABBOTT LAB (US) | 1995-02-17 | — | — | EP | claimed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | CHRNA1, CHRNG, CHRNA4 | CHRNB2 14/4885CHRNA4 3/4885CHRNB4 9/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885CHRNB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.